At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.
Provista’s highly experienced leadership team has a proven track record in successfully commercializing new diagnostic products. The team operates from the company’s core values that stress candor in all communications, integrity across business facets, and the courage to pursue a bold vision to improve the detection and monitoring of women’s cancers.
Provista is currently developing several blood-based diagnostic tests to address the greatest unmet needs and clinical challenges in women’s cancers, including breast, ovarian, endometrial and HPV-associated cancers. Provista’s blood-based approach is designed to complement the current standard-of-care, providing an additional diagnostic tool for early detection.
Leveraging its ProteoMark Technology platform, Provista will be innovating a blood-based diagnostic test to aid in the detection and management of endometrial cancer.